[go: up one dir, main page]

DK0552256T3 - Fremgangsmåde til at behandle eller forebygge type 1 diabetes ved peroral indgivelse af insulin - Google Patents

Fremgangsmåde til at behandle eller forebygge type 1 diabetes ved peroral indgivelse af insulin

Info

Publication number
DK0552256T3
DK0552256T3 DK91918981T DK91918981T DK0552256T3 DK 0552256 T3 DK0552256 T3 DK 0552256T3 DK 91918981 T DK91918981 T DK 91918981T DK 91918981 T DK91918981 T DK 91918981T DK 0552256 T3 DK0552256 T3 DK 0552256T3
Authority
DK
Denmark
Prior art keywords
insulin
diabetes
treating
oral administration
preventing type
Prior art date
Application number
DK91918981T
Other languages
Danish (da)
English (en)
Inventor
Howard L Weiner
David A Hafler
George Eisenbarth
Zhengri Zhang
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Application granted granted Critical
Publication of DK0552256T3 publication Critical patent/DK0552256T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK91918981T 1990-10-10 1991-10-10 Fremgangsmåde til at behandle eller forebygge type 1 diabetes ved peroral indgivelse af insulin DK0552256T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59546890A 1990-10-10 1990-10-10
PCT/US1991/007475 WO1992006704A1 (fr) 1990-10-10 1991-10-10 Methodes servant a traiter ou a prevenir le diabete du type 1 par administration orale d'insuline

Publications (1)

Publication Number Publication Date
DK0552256T3 true DK0552256T3 (da) 2001-12-10

Family

ID=24383359

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91918981T DK0552256T3 (da) 1990-10-10 1991-10-10 Fremgangsmåde til at behandle eller forebygge type 1 diabetes ved peroral indgivelse af insulin

Country Status (15)

Country Link
US (5) US5763396A (fr)
EP (1) EP0552256B1 (fr)
JP (1) JP2548056B2 (fr)
KR (1) KR100239743B1 (fr)
AT (1) ATE204178T1 (fr)
AU (1) AU659419B2 (fr)
BR (1) BR9106977A (fr)
CA (1) CA2093806C (fr)
DE (1) DE69132688T2 (fr)
DK (1) DK0552256T3 (fr)
ES (1) ES2162615T3 (fr)
HU (2) HUT64235A (fr)
IL (1) IL99699A (fr)
NO (1) NO319370B1 (fr)
WO (1) WO1992006704A1 (fr)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US7448375B2 (en) * 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
GB9319429D0 (en) * 1993-09-21 1993-11-03 London Health Ass Methods and products for controlling immune responses in mammals
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
ES2197212T3 (es) * 1994-12-22 2004-01-01 Astrazeneca Ab Preparacion terapeutica para inhalacion que contiene la hormona paratiroidea, pth.
EE9700138A (et) 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
EP0835129B1 (fr) 1995-06-30 2003-10-29 Novo Nordisk A/S Prevention d'une maladie presentant les caracteristiques du diabete
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
WO1997009061A1 (fr) * 1995-09-06 1997-03-13 Alexion Pharmaceuticals, Inc. Traitement du diabete par l'administration d'insuline n'ayant pas d'effet hormonal
SE520392C2 (sv) * 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US20050025758A1 (en) * 1996-10-01 2005-02-03 Harrison Leonard Charles Method and compositions for treatment of insulin-dependant diabetes mellitus
CA2252790A1 (fr) * 1997-02-28 1998-09-03 Enzo Therapeutics, Inc. Nouveaux procedes de retro-regulation immunitaire selective (sidr)
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
US20060239930A1 (en) * 1997-08-04 2006-10-26 Herbert Lamche Process for nebulizing aqueous compositions containing highly concentrated insulin
US6068844A (en) * 1997-12-19 2000-05-30 The United States Of America As Represented By The Department Of Health And Human Services Increased resistance to stroke by developing immunologic tolerance to myelin or components thereof
US5945123A (en) * 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
US20040062802A1 (en) * 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US6417208B1 (en) * 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
US7534605B2 (en) 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
CA2274414A1 (fr) * 1999-06-11 2000-12-11 Universite Laval Proteine de poisson alimentaire a utiliser pour restaurer la fonction normale de l'insuline chez les personnes insulinoresistantes
EP1808438B1 (fr) * 1999-06-29 2014-10-01 MannKind Corporation Purification et stabilisation de peptide et protéines dans des agents pharmaceutiques
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
RU2155602C1 (ru) * 1999-11-30 2000-09-10 Оао "Куантум Сатис" Инсулинсодержащее лекарственное средство для перорального применения и способ его получения
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US20100303769A1 (en) * 2000-04-06 2010-12-02 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US7166280B2 (en) * 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US6543682B1 (en) 2000-05-03 2003-04-08 Nichole Glaser Insulin-dose calculator disk
EP1286664B1 (fr) * 2000-05-12 2007-07-25 Oregon Health and Science University Combinaison de faibles doses d'oestrogene et d'agents immunotherapeutiques pour traiter les maladies immunitaires
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
ES2292594T3 (es) 2000-05-24 2008-03-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services E-selectina para tratar o prevenir accidentes cerebrovasculares.
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
EP1387713A1 (fr) * 2001-05-04 2004-02-11 Pfizer Products Inc. Methode pour prevenir le diabete de type 2 au moyen d'insuline sous forme d'aerosol
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
AU2004233691B2 (en) * 2003-04-28 2007-09-20 Sankyo Company, Limited Sugar intake-ability enhancer
AU2004233693B2 (en) * 2003-04-28 2007-07-19 Funahashi, Toru Adiponectin production enhancer
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
ES2584867T3 (es) * 2004-01-12 2016-09-29 Mannkind Corporation Un método que reduce los niveles séricos de proinsulina en diabéticos de tipo 2
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
WO2005089722A1 (fr) * 2004-03-12 2005-09-29 Biodel, Inc. Composition pour administration de medicament avec action rapide
CA2570916C (fr) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Forme posologique d'ipp a doses multiples
CN103223160B (zh) 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
CA2575604A1 (fr) * 2004-07-30 2006-02-02 Oregon Health And Science University Procedes de detection et de traitement de troubles auto-immuns
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
WO2007033372A2 (fr) 2005-09-14 2007-03-22 Mannkind Corporation Procede de preparation de medicaments fonde sur l'accroissement de l'affinite des surfaces de microparticules cristallines pour des principes actifs
EP1931665A1 (fr) 2005-09-20 2008-06-18 Schering Corporation La 1-[[1-[(2-amin0-6-methyl-4-pyridinyl) methyl]-4-flu0r0-4-piperidinyl,]carbonyl]-4-[2-(2-pyridinyl)-3h-imidaz0[4, 5-b]pyridin-3-yl]piperidine, utile en tant qu'antagoniste de l'histamine h3
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (fr) * 2005-09-29 2007-04-12 Biodel, Inc. Preparations d'insuline a action rapide et prolongee
DK1986679T3 (da) 2006-02-22 2017-11-20 Mannkind Corp Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
CA2649109A1 (fr) * 2006-04-12 2007-10-25 Biodel, Inc. Formulations de combinaison d'insuline a action prolongee et a action rapide
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
EP2134351B1 (fr) 2007-03-13 2016-04-27 Nutrition 21, Inc. Procédés et compositions utilisés pour la libération prolongée de chrome
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009002867A2 (fr) 2007-06-26 2008-12-31 Nutrition 21, Inc. Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
EP2203068A4 (fr) 2007-10-12 2012-08-22 Takeda Pharmaceuticals Usa Inc Procédés de traitement de troubles gastro-intestinaux indépendants de la prise alimentaire
PT2203181T (pt) 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
MX2010004450A (es) 2007-10-22 2010-05-05 Schering Corp Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
EP2077132A1 (fr) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispositif distributeur, dispositif de stockage et procédé pour la distribution d'une formulation
JP5352596B2 (ja) * 2008-01-04 2013-11-27 バイオデル， インコーポレイテッド 組織グルコースレベルの関数としてのインスリン放出のためのインスリン製剤
AU2009249237A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA3153292A1 (fr) 2008-06-13 2009-12-17 Mannkind Corporation Inhalateur de poudre seche et systeme d'administration de medicament
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN102065942B (zh) 2008-06-20 2013-12-11 曼金德公司 用于对吸入工作进行实时描绘的交互式设备和方法
AU2009270971A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
EP2318388A2 (fr) 2008-07-23 2011-05-11 Schering Corporation Dérivés spirocycliques tricycliques et leurs procédés d utilisation
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
WO2010039789A1 (fr) 2008-10-03 2010-04-08 Schering Corporation Dérivés de spiro-imidazolone utilisés en tant qu'antagonistes des récepteurs du glucagon
JP2012505899A (ja) 2008-10-16 2012-03-08 シェーリング コーポレイション アジン誘導体およびそれの使用方法
EP2379562A1 (fr) 2008-12-16 2011-10-26 Schering Corporation Dérivés de pyranone bicyclique comme agonistes du récepteur de l'acide nicotinique
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010071822A1 (fr) 2008-12-19 2010-06-24 Schering Corporation Dérivés de pipéridine et de pipérazine et leurs méthodes d'utilisation
US8283360B2 (en) 2008-12-19 2012-10-09 Merck Sharp & Dohme Corp. Bicyclic heterocyclic derivatives and methods of use thereof
WO2010075273A1 (fr) 2008-12-23 2010-07-01 Schering Corporation Dérivés d'hétérocycles bicycliques et leurs procédés d'utilisation
EP2382203B1 (fr) 2008-12-23 2015-01-14 Merck Sharp & Dohme Corp. Dérivés d'hétérocycles bicycliques et leurs procédés d'utilisation
US8722882B2 (en) 2008-12-23 2014-05-13 Merck Sharp & Dohme Corp. Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP5508438B2 (ja) 2009-01-28 2014-05-28 スマートセルズ・インコーポレイテツド 制御された薬物送達のための複合体に基づくシステム
WO2010092218A2 (fr) 2009-02-12 2010-08-19 Proyecto De Biomedicina Cima, S.L. Utilisation de la cardiotrophine-1 pour le traitement de maladies métaboliques
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
AU2010226829A1 (en) 2009-03-18 2011-09-15 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
WO2010114957A1 (fr) 2009-04-03 2010-10-07 Schering Corporation Dérivés de pipéridine et de pipérazine bicycliques en tant que modulateurs de rcpg pour le traitement de l'obésité, du diabète et d'autres troubles métaboliques
JP5763053B2 (ja) 2009-05-18 2015-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アダプタ、吸入器具及びアトマイザ
WO2010144664A1 (fr) 2009-06-12 2010-12-16 Schering Corporation Thiophènes en tant qu'antagonistes du récepteur du glucagon, compositions, et leurs procédés d'utilisation
KR20180036807A (ko) 2009-06-12 2018-04-09 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
US20120172369A1 (en) 2009-09-14 2012-07-05 Ting Pauline C Inhibitors of diacylglycerol acyltransferase
EP2485735B1 (fr) 2009-10-08 2015-07-29 Merck Sharp & Dohme Corp. Inhibiteurs de protéines de liaison aux acides gras (fabp)
US9409918B2 (en) 2009-10-29 2016-08-09 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
CA2778698A1 (fr) 2009-11-03 2011-05-12 Mannkind Corporation Appareil et methode de simulation d'efforts d'inhalation
WO2011062889A1 (fr) 2009-11-23 2011-05-26 Schering Corporation Dérivés d'éther de pyrimidine et leurs procédés d'utilisation
EP2504010A4 (fr) 2009-11-23 2013-04-17 Merck Sharp & Dohme Dérivés de pyrimidine bicycliques fusionnées et leurs procédés d'utilisation
WO2011066137A1 (fr) 2009-11-24 2011-06-03 Schering Corporation Dérivés de biaryle substitué et leurs procédés d'utilisation
EP2504051B1 (fr) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nébuliseur
AP3141A (en) 2009-11-25 2015-02-28 Boehringer Ingelheim Int Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
CA2806399A1 (fr) 2010-07-28 2012-02-02 Smartcells, Inc. Polypeptides d'insuline exprimes de facon recombinante et utilisations de ceux-ci
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8603527B2 (en) * 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
CN105749253A (zh) 2011-03-01 2016-07-13 Jds治疗有限公司 用于预防和治疗糖尿病、低血糖症及相关病症的胰岛素和铬组合物
WO2012130757A1 (fr) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Appareil médical pourvu d'un récipient
KR101940832B1 (ko) 2011-04-01 2019-01-21 맨카인드 코포레이션 의약 카트리지용 블리스터 패키지
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
EP2776053A1 (fr) 2011-10-24 2014-09-17 MannKind Corporation Procédés et compositions pour traiter la douleur
WO2013152894A1 (fr) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Pulvérisateur comprenant des moyens de détrompage
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
WO2014057522A1 (fr) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions et procédés de traitement de la stéatohépatite non alcoolique
EP2911690A1 (fr) 2012-10-26 2015-09-02 MannKind Corporation Compositions et procédés de vaccin antigrippal inhalable
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
WO2014151206A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
JP6442412B2 (ja) 2013-03-15 2018-12-19 持田製薬株式会社 非アルコール性脂肪性肝炎治療のための組成物および方法
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EP4424697A3 (fr) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Agonistes ultra-purs de guanylate cyclase c, leur procédé de fabrication et d'utilisation
CA2918369C (fr) 2013-07-18 2021-06-29 Mannkind Corporation Compositions pharmaceutiques en poudre seche stables a la chaleur et procedes
WO2015021064A1 (fr) 2013-08-05 2015-02-12 Mannkind Corporation Appareil d'insufflation et procédés
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
US9744313B2 (en) 2013-08-09 2017-08-29 Boehringer Ingelheim International Gmbh Nebulizer
MX366852B (es) 2013-10-04 2019-07-25 Merck Sharp & Dohme Conjugados de insulina sensibles a glucosa.
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
PE20210959A1 (es) 2014-05-07 2021-05-25 Boehringer Ingelheim Int Nebulizador, dispositivo indicador y recipiente
ES2874029T3 (es) 2014-05-07 2021-11-04 Boehringer Ingelheim Int Nebulizador
CN106255554B (zh) 2014-05-07 2021-05-04 勃林格殷格翰国际有限公司 容器、喷雾器及用途
CA2951984C (fr) 2014-07-15 2023-10-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Polypeptides isoles de cd44 et utilisations associees
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
HUE054694T2 (hu) 2014-10-06 2021-09-28 Signal Pharm Llc Szubsztituált aminpurin vegyületek, ezek összetételei, és az ezekkel végzett kezelések módszerei
CA2936740C (fr) 2014-10-31 2017-10-10 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
CN109069532A (zh) 2016-02-11 2018-12-21 营养21有限责任公司 含铬组合物用于改善健康和健身
SG10202009589UA (en) 2016-04-01 2020-10-29 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CN109819649B (zh) 2016-04-01 2023-02-28 西格诺药品有限公司 氨基嘌呤化合物的固体形式及其使用方法
WO2019070827A1 (fr) 2017-10-04 2019-04-11 Celgene Corporation Procédés de préparation de cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-méthylcyclohexane-1-carboxamide
CA3078368A1 (fr) 2017-10-04 2019-04-11 Celgene Corporation Compositions et methodes d'utilisation du cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl] amino}-8-(2,4,6-trichloroanilino)-9h-purine-9-yl]-1-methylcyclohexane-1-carboxamide
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
WO2023200363A1 (fr) * 2022-04-13 2023-10-19 Фания Иршатовна МАГАНОВА Procédé de production d'une forme orale d'une substance contenant de l'insuline

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) * 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3594476A (en) * 1969-05-12 1971-07-20 Massachusetts Inst Technology Submicron aqueous aerosols containing lecithin
US3703173A (en) * 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1527605A (en) * 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
IT1133010B (it) * 1980-05-15 1986-07-09 Sigma Tau Ind Farmaceuti Metodo terapuetico per il trattamento del diabete mellito a insorgenza giovanile e composizione farmaceutica per tale metodo
DK283180A (da) * 1980-07-01 1982-01-02 Novo Industri As Polypeptider og derivater deraf
SU1011126A1 (ru) * 1981-07-14 1983-04-15 Всесоюзный научно-исследовательский и испытательный институт медицинской техники Средство дл лечени сахарного диабета
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
EP0179904A1 (fr) * 1984-05-09 1986-05-07 Medaphore Inc. Insuline administree par voie orale et son procede de preparation
US4963526A (en) * 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
EP0200383A3 (fr) * 1985-04-15 1987-09-02 Eli Lilly And Company Procédé pour administrer l'insuline
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
DK179286D0 (da) * 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
JPS62267238A (ja) * 1986-05-15 1987-11-19 R P Shiila- Kk インシユリン坐剤の製法
WO1988001213A1 (fr) * 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Systemes de distribution pour agents pharmacologiques
GB8622218D0 (en) * 1986-09-16 1986-10-22 Renishaw Plc Calibration for automatic machine tool
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
EP0359783B2 (fr) * 1987-06-24 2002-04-17 Autoimmune, Inc. Traitement de maladies auto-immunitaires par administration orale d'auto-antigenes
US5571499A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5399347A (en) 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5641474A (en) 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5843445A (en) 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5645820A (en) 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US4992417A (en) * 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US4789660A (en) * 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
EP0308181A1 (fr) * 1987-09-14 1989-03-22 Novo Nordisk A/S Formulations à délivrance transmucosale et méthode de préparation
ES2045276T3 (es) * 1988-07-21 1994-01-16 Hoffmann La Roche Preparacion de insulina
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5171737A (en) * 1989-03-03 1992-12-15 The Liposome Company, Inc. Emulsions
AU670024B2 (en) 1989-07-14 1996-07-04 Autoimmune, Inc. Methods of treating or preventing autoimmune uveoretinitis in mammals
ES2144398T3 (es) * 1989-12-20 2000-06-16 Autoimmune Inc Tratamiento mejorado de enfermedades autoinmunes mediante la administracion en aerosol de autoantigenos.
AU651097B2 (en) 1990-03-02 1994-07-14 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
IL97709A (en) 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
IL99864A (en) 1990-10-31 2000-11-21 Autoimmune Inc Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5672581A (en) * 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation

Also Published As

Publication number Publication date
EP0552256B1 (fr) 2001-08-16
US20010056063A1 (en) 2001-12-27
BR9106977A (pt) 1993-08-31
CA2093806A1 (fr) 1992-04-11
WO1992006704A1 (fr) 1992-04-30
US5763396A (en) 1998-06-09
HUT64235A (en) 1993-12-28
US5843886A (en) 1998-12-01
NO319370B1 (no) 2005-07-25
IL99699A (en) 2002-04-21
EP0552256A1 (fr) 1993-07-28
EP0552256A4 (fr) 1994-04-27
US6703361B2 (en) 2004-03-09
AU659419B2 (en) 1995-05-18
DE69132688D1 (de) 2001-09-20
HU225054B1 (en) 2006-05-29
IL99699A0 (en) 1992-08-18
US5858968A (en) 1999-01-12
US5643868A (en) 1997-07-01
JP2548056B2 (ja) 1996-10-30
NO931267D0 (no) 1993-04-01
AU8767991A (en) 1992-05-20
CA2093806C (fr) 2003-12-30
ATE204178T1 (de) 2001-09-15
JPH06504986A (ja) 1994-06-09
KR930702022A (ko) 1993-09-08
DE69132688T2 (de) 2001-11-29
NO931267L (no) 1993-05-05
KR100239743B1 (ko) 2000-02-01
ES2162615T3 (es) 2002-01-01

Similar Documents

Publication Publication Date Title
DK0552256T3 (da) Fremgangsmåde til at behandle eller forebygge type 1 diabetes ved peroral indgivelse af insulin
DE69127470D1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
IT1241996B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
DK395689D0 (da) Pharmaceutisk tilberedning til behandling af diabetes mellitus
HUP0002373A2 (hu) Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
BR9906796A (pt) Método para a administração de análogos de insulina monoméricos
IT1241997B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
SE9702401D0 (sv) Pharmaceutical use
NO870560L (no) Nytt farmasoeytisk preparat.
DK163181C (da) Analogifremgangsmaade til fremstilling af n,n'-di(arylalkylen)alkylendiaminer eller farmaceutisk acceptable salte deraf
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
KR890004705A (ko) 항바이러스성 제제
KR890012942A (ko) 5-치환된 오르니틴 유도체
KR880004810A (ko) 소화성 궤양 치료제
DK623984D0 (da) Farmaceutisk doseringsenhed
KR890002058A (ko) 간질 및 불안 상태의 예방 및 치료용 2,4,6-트리스-3-급-부틸아미노-1,-3,-5-트리아진
KR960007619A (ko) 신규 알긴산 유도체 및 그 제조방법